Report : Europe Cell Therapy Bioprocessing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (Bioreactor, Lyophilization, Electrospinning, Control flow Centrifugation, Ultrasonic Lysis, Genome Editing Technology, Cell Immortalization Technology, and Viral Vector Technology); Cell Type (Stem Cell, Immune Cell, Human Embryonic Stem Cell, Pluripotent Stem Cell, and Hematopoietic Stem Cells), Indication (Cardiovascular Disease (CVD), Oncology, Wound Healing, Orthopaedic, and Others); End User (Hospitals and Clinics, Diagnostic Centres, Regenerative Medicine Centres, and Academic and Research Institute)
Bioreactor Segment has the Largest Share of Technology in the Europe Cell Therapy Bioprocessing Market during 2021–2028
According to a new market research study on “Europe Cell Therapy Bioprocessing Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Technology, Cell Type, Indication, and End User” is expected to reach US$ 8,652.1 million by 2028 from US$ 3,627.3 million in 2021. The market is estimated to grow at a CAGR of 13.2% from 2021 to 2028. The report provides trends prevailing in the Europe Cell therapy bioprocessing market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing investments for cell and gene therapy manufacturing, and growing approvals for cell therapies are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the challenges such as high cost of product, regulatory challenges, and logistics challenges.
As expected, many companies, including hardware and service providers, are increasing their pandemic-related R&D and manufacturing. Suppliers are bracing for increased business as companies and governments rush to develop, test, and deploy pandemic-related vaccines, therapeutics, and diagnostics. There has also been a demand for increased short-term supply stockpiling. However, in long run the demand for the cell therapy bioprocessing is expected to increase owing to supportive government initiatives. For instance, UK government has allotted 100 million Euros funds to the Cell and Gene Therapy Catapult Manufacturing Innovation Centre to expedite the production of a vaccine for COVID-19 in the UK. Moreover, Stempeutics Research has filed application seeking European Commission Funding to develop cell therapy for COVID 19. The company has also entered into partnership with global consortium of cell therapy companies to gather funding for cell therapy research from European commission. Hence, Europe Cell therapy bioprocessing market is likely to show significant growth prospects during this pandemic and forecasted year.
The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, in 2020, the bioreactor segment accounted for the cell therapy bioprocessing market's most significant market share. The segment's growth is expected due to its utilization for making cells and scaling up the volume for cellular products. Bioreactors are the primary equipment required during the cell therapy bioprocessing thus are expected to continue their dominancy during the forecast period. However, the genome-editing technology segment is expected to grow at the fastest CAGR. Genome editing technology is widely used for targeting and designing the cellular and genes for cell therapies.
Fresenius Kabi Ag., Asahi Kasei Corporation, Sartorius Ag, Merck Kgaa, Thermo Fisher Scientific Inc., Corning Incorporated, Cytiva (Ge Healthcare), Lonza, Repligen, and Catalent Inc are among the leading companies in the Europe cell therapy bioprocessing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in January 2021, Sartorius Partners with RoosterBio. The partnership seeks to drive the scale-up of hMSC production for regenerative medicine by exploiting both companies' best-in-class solutions to dramatically minimise process development efforts, industrialise the supply chain, and accelerate the growth and commercialization of game-changing cell-based regenerative cures.
The market for cell therapy bioprocessing market is segmented into technology, cell type, indication, and end user. Based on technology, the Cell therapy bioprocessing market is segmented into bioreactor, lyophilization, electrospinning, control flow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. Based on cell type, the cell therapy bioprocessing market is segmented into stem cell, immune cell, human embryonic stem cell, pluripotent stem cell, and hematopoietic stem cells. Based on indication, the cell therapy bioprocessing market is segmented into cardiovascular disease (cvd), oncology, wound healing, orthopaedic, and others. Based on end user, the cell therapy bioprocessing market is segmented into hospitals and clinics, diagnostic centres, regenerative medicine centres, and academic and research institute. Geographically, the cell therapy bioprocessing market is segmented into Europe (Germany, UK, France, Spain, Italy, Rest of Europe).
Contact Person: Sameer Joshi
Email Id: email@example.com